NCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
Clinical Trials
24 trialsNCT06065592 2023-10-06
CAT_PB
Lebanese University
Phase 1 Unknown
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT05135104 2023-05-17
PALBO
Asociatia Oncohelp - Centrul de Oncologie Oncohelp
Unknown
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT04334330 2022-05-02
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
Sun Yat-sen University
Phase 2 Unknown
NCT04669587 2022-03-22
ENZENO
EnhancedBio Inc.
Phase 1/2 Unknown
NCT02626507 2022-02-09
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
Hoffman Oncology
Phase 1 Unknown
NCT03633331 2021-10-15
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Unknown
NCT05076695 2021-10-13
NeoTPPF
Fudan University
Phase 2 Unknown
NCT05051956 2021-09-21
Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?
Namik Kemal University
Unknown
NCT04047758 2021-07-20
Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer
Shengjing Hospital
Phase 3 Unknown
NCT04858997 2021-07-15
Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04856371 2021-04-23
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
Haihe Biopharma Co., Ltd.
Phase 1 Unknown
NCT04852081 2021-04-21
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
Blokhin's Russian Cancer Research Center
Unknown
NCT04526028 2020-08-25
Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China
Tianjin Medical University Cancer Institute and Hospital
Unknown
NCT04247633 2020-04-20
High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)
Samsung Medical Center
Phase 2 Unknown
NCT04318223 2020-03-23
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy
Consorzio Oncotech
Phase 2 Unknown
NCT04289974 2020-02-28
Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer
ChineseAMS
Unknown
NCT02690480 2020-02-05
FLIPPER
Spanish Breast Cancer Research Group
Phase 2 Unknown
NCT02592746 2019-04-08
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
Samsung Medical Center
Phase 2 Unknown
NCT03756090 2018-12-07
PECP
Zhejiang Cancer Hospital
Phase NA Unknown
NCT03560856 2018-06-18
PALPETBIO
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT01709370 2013-12-31
Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women
Organisation for Oncology and Translational Research
Phase 2 Unknown